Among patients with gout in the US, Black individuals and those living in the South were associated with reduced adherence to allopurinol.

Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, ...

The third phase, inter-critical gout, is a period between acute attacks when the patient is symptom-free. Finally, chronic ...

Uric acid crystals can accumulate under the skin and form lumps called "tophi." Chronic (long-term) gout can cause knee ...

The current strategy for managing chronic gout is the use of uric-acid-lowering drugs to reduce urate production or of a uricosuric agent to promote renal uric acid excretion. Probenecid is ...

Gout is a disease characterized by recurrent attacks of arthritis, in which uric acid appears in excessive amounts in the ...

Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...